Search

everythinglearnresearchcommunity

for

Search:↓

Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.

Low testosterone does not prevent prostate cancer in men with type 1 diabetes.

The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.

The document concludes that blocking the internal pathways that create androgens might help treat cancers that depend on sex hormones.

The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

The protein StAR is found in 17 different organs and can affect hair loss and brain functions, but its full role is not yet fully understood.

Rare adrenal cancers that secrete androgens or estrogens have a poor prognosis and are treated primarily with surgery.

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.

A woman's mature cystic teratoma caused her virilization by producing testosterone.

Human skin produces sex hormones like estrogen and testosterone, influenced by ARO and StAR, which may affect skin elasticity and hair growth.

Steroid sulfatase is important for activating hormones that affect memory, brain function, and certain diseases, and could be a target for treating hormone-related disorders.

The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.

A group has developed therapies that show promise for treating cancer and various other conditions.

A new method accurately measures nine specific hormones in human blood.

A 68-year-old woman developed male traits due to a tumor in her ovary, which was removed, returning her hormone levels to normal.

The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.

Gene therapy shows promise for treating skin disorders and cancer, but faces technical challenges.

Markers CRABP1, Nestin, and Ephrin B2 are present in skin cancer environments and may influence their development.

The drug combination was safe and showed promise in treating advanced tumors.

Cepharanthine has many medicinal uses but needs improvement for better effectiveness.

A postmenopausal woman's masculine symptoms improved after surgery for a hormone-producing ovarian tumor.

50-nm nanoparticles are better at penetrating skin and targeting hair follicles for drug delivery than 100-nm ones.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Combining flutamide and finasteride can reduce prostate weight and tumor growth, potentially benefiting treatments needing optimal DHT inhibition.

New compounds may help treat prostate cancer by reducing cell growth.